Infection by Plasmodium vivax poses unique challenges for diagnosis and treatment.
Relatively low numbers of parasites in peripheral circulation may be difficult to confirm, and …

The incidence and range of endemic malaria caused by Plasmodium vivax has expanded
during the past 30 years. This parasite forms hypnozoites in the liver, creating a persistent …

There is inadequate understanding of the biology, pathology, transmission, and control of
Plasmodium vivax, the geographically most widespread cause of human malaria. During the …

Plasmodium vivax is a significant public health threat throughout most of the tropics and to
travelers to these regions. The infection causes a debilitating febrile syndrome that often …

The gravity of the threat posed by vivax malaria to public health has been poorly
appreciated. The widely held misperception of Plasmodium vivax as being relatively …

Plasmodium vivax represents a special challenge to malaria control because of the ability of
a single infection to relapse over months to years. P. vivax is more tolerant of low …

Plasmodium vivax infects 130–435 million of the 2.6 billion people living at risk of infection.
Recent studies suggest that vivax malaria can become lethal in a similar way to severe …

Focus on Plasmodium vivax: Trends in Parasitology Skip to Main Content Advertisement
Trends in Parasitology This journal offers authors two options (open access or subscription) to …

Effective use of anti-malarial drugs is key to reducing the transmission potential of
Plasmodium vivax. In patients presenting with symptomatic disease, treatment with potent …

The standard adult treatment regimen for Plasmodium vivax malaria is chloroquine (1500
mg over 3 d) plus primaquine (15 or 30 mg daily for 14 d), but patient compliance tends to be …